Nanxin Pharmaceutical announced that the company participated in the 2026 online collective reception day and semi-annual results briefing for investors of listed companies in Hunan. Phase III clinical trials of the improved new drug paramivir inhalation solution have reached the pre-set end point, and pre-NDA communication has been initiated; Phase II clinical trials of the Class 1 innovative drug meflunidone tablets have been registered and statistical analysis is being carried out; butylphthalate oral freeze-dried powder promotes phase I clinical trials; acetaminophen mannitol injections have been registered and accepted; preparations related to levosalbutol hydrochloride have obtained marketing approval. The transfer amount of 51.7567 million yuan of accounts receivable transferred by the company to the controlling shareholder has all been paid. We still lost money in the first half of 2026, did not meet the dividend requirements, and there is no clear repurchase plan yet. The net cash flow from operating activities in the first half of the year was RMB 12 million, mainly due to a decrease in sales of goods sold.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.